Athersys (OTCPK:ATHX.Q) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

ATHX.Q 주식 개요

생명공학 기업인 Athersys는 재생 의학 분야의 연구 개발 활동에 주력하고 있습니다.

ATHX.Q 기본 분석
눈송이 점수
가치 평가	1/6
미래 성장	0/6
과거 실적	0/6
재무 상태	0/6
배당금	0/6

보상

위험 분석

지난 5년간 매년 수익이 12.5% 씩 감소했습니다.

의미 있는 시가총액이 없습니다. ( $253K )

마이너스 주주 지분

지난 1년 동안 주주가 크게 희석되었습니다.

+ 3 더 많은 위험

Athersys, Inc. 경쟁사

Athenex

OTCPK:ATNX.Q

US$131.7k

Peak Bio

OTCPK:PKBO

US$222.0k

Endonovo Therapeutics

OTCPK:ENDV

US$416.7k

Acorda Therapeutics

OTCPK:ACOR.Q

US$326.1k

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Athersys
과거 주가
현재 주가	US$0.0032
52주 최고치	US$0.93
52주 최저치	US$0.0018
베타	-1.07
11개월 변경	-46.67%
3개월 변경 사항	45.45%
1년 변경 사항	-99.63%
33년 변화	-99.99%
5년 변화	-99.99%
IPO 이후 변화	-100.00%

최근 뉴스 및 업데이트

Recent updates

One Analyst's Revenue Estimates For Athersys, Inc. (NASDAQ:ATHX) Are Surging Higher

Aug 16

Athersys stock falls ~9% after reporting Q2 loss, fall in cash and cash equivalents

Aug 12

Kasey Rosado named interim CFO of Athersys

Aug 04

Athersys: Dead Man Walking

Jul 25

Athersys: Focus On Stroke

May 04

Athersys - Hero Or Zero Opportunity

Apr 18

Athersys: Near-Term Progress In Stem Cell Phase 3 Trials Could Multiply Shares In 2022

Jan 20

Here's Why Athersys (NASDAQ:ATHX) Must Use Its Cash Wisely

Dec 30

Athersys: COVID-ARDS Is The Company's Most Important Target

Nov 25

Athersys Shares Are Ready To Rumble Following Period Of Turmoil

Aug 30

Athersys: Subgroup Analysis As A Masterstroke

Jul 29

Here's Why We're Watching Athersys' (NASDAQ:ATHX) Cash Burn Situation

May 28

Is Athersys (NASDAQ:ATHX) In A Good Position To Invest In Growth?

Feb 27

Update On Athersys - Trying To Read Between The Lines

Feb 03

Athersys: Risky Financial Position, But Promising Upside By FYE 2023

Feb 01

Athersys: Stem Cell Opportunity For Risk Tolerant Investors

Nov 12

주주 수익률

	ATHX.Q	US Biotechs	US 마켓
7D	-3.0%	-0.7%	0.07%
1Y	-99.6%	10.2%	20.7%

수익률 대 산업: ATHX.Q 지난 1년 동안 6.7 %를 반환한 US Biotechs 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: ATHX.Q 지난 1년 동안 23.3 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is ATHX.Q's price volatile compared to industry and market?
ATHX.Q volatility
ATHX.Q Average Weekly Movement	45.4%
Biotechs Industry Average Movement	10.4%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.3%
10% least volatile stocks in US Market	2.8%

안정적인 주가: ATHX.Q 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: ATHX.Q 의 주간 변동성( 45% )은 지난 1년 동안 안정적이었지만 여전히 US 의 75%보다 높습니다. 주식.

회사 소개

설립	직원	CEO	웹사이트
1995	24	n/a	www.athersys.com

생명공학 회사인 Athersys는 재생 의학 분야의 연구 개발 활동에 주력하고 있습니다. 임상 개발 프로그램은 신경 질환, 심혈관 질환, 염증 및 면역 질환, 폐 및 기타 질환을 치료하는 데 중점을 두고 있습니다. 회사의 주요 플랫폼 제품으로는 허혈성 뇌졸중으로 인한 신경학적 손상으로 고통받는 환자를 치료하고 급성 호흡곤란 증후군, 외상 합병증, HSC 이식 지원 및 기타 적응증을 위한 동종 줄기세포 제품인 멀티스템 세포 치료제가 있습니다.

Athersys, Inc. 기본 사항 요약

Athersys 의 수익과 매출은 시가총액과 어떻게 비교하나요?
ATHX.Q 기본 통계
시가총액	US$197.59k
수익(TTM)	-US$37.51m
수익(TTM)	US$80.00k

2.5x

P/S 비율

0.0x

P/E 비율

ATHX.Q 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
ATHX.Q 손익 계산서(TTM)
수익	US$80.00k
수익 비용	US$18.78m
총 이익	-US$18.69m
기타 비용	US$18.81m
수익	-US$37.51m

최근 보고된 수익

Sep 30, 2023

다음 수익 날짜

n/a

주당 순이익(EPS)	-0.61
총 마진	-23,368.75%
순이익 마진	-46,883.75%
부채/자본 비율	-29.6%

ATHX.Q 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

ATHX.Q 주식 개요

보상

위험 분석

Athersys, Inc. 경쟁사

OTCPK:ATNX.Q

US$131.7k

OTCPK:PKBO

US$222.0k

OTCPK:ENDV

US$416.7k

OTCPK:ACOR.Q

US$326.1k

가격 내역 및 성능

최근 뉴스 및 업데이트

Motion for Case Conversion Filed by Athersys, Inc.

Healios K.K. (TSE:4593) completed the acquisition of Substantially all assets of Abt Holding Company, Advanced Biotherapeutics, Inc, Athersys, Inc. (OTCPK:ATHX.Q), ReGenesys BVBA and ReGenesys, LLC .

Athersys, Inc. announced delayed annual 10-K filing

Motion for Joint Administration Filed by Athersys, Inc.

Athersys, Inc. Announces Termination of Daniel A. Camardo as Chief Executive Officer, Effective from December 31, 2023

Athersys, Inc. announced delayed 10-Q filing

Recent updates

Motion for Case Conversion Filed by Athersys, Inc.

Healios K.K. (TSE:4593) completed the acquisition of Substantially all assets of Abt Holding Company, Advanced Biotherapeutics, Inc, Athersys, Inc. (OTCPK:ATHX.Q), ReGenesys BVBA and ReGenesys, LLC .

Athersys, Inc. announced delayed annual 10-K filing

Motion for Joint Administration Filed by Athersys, Inc.

Athersys, Inc. Announces Termination of Daniel A. Camardo as Chief Executive Officer, Effective from December 31, 2023

Athersys, Inc. announced delayed 10-Q filing

Athersys, Inc.(OTCPK:ATHX) dropped from S&P TMI Index

Athersys, Inc. Receives A Delisting Determination Letter from Nasdaq

Athersys, Inc. Reports Interim Analysis Results of MASTERS-2 Clinical Study with Multistem in Ischemic Stroke

Athersys, Inc. Appoints Jane Wasman as Board Chair

Athersys, Inc. has completed a Follow-on Equity Offering in the amount of $3.5 million.

Athersys, Inc. announced delayed 10-Q filing

Athersys, Inc. Appoints Neema Mayhugh to Its Board of Directors, Nominations, Governance and Compliance Committee, Compensation Committee and Audit Committee

New major risk - Market cap size

Athersys Receives Written Notice from Nasdaq Regarding Non-Compliance with Minimum Closing Bid Price Requirement

Athersys, Inc., Annual General Meeting, Sep 27, 2023

Athersys, Inc. Announces Patient Enrollment Begins in Third and Final Cohort of the Phase 2 Matrics-1 Clinical Study Evaluating Athersys' Multistem Following Hemorrhagic Trauma

Athersys Granted Clinical Type B Meeting with FDA for Masters-2 Clinical Trial Protocol Discussion

Athersys, Inc. Provides an Update on Ongoing Clinical Trials with MultiStem for the Treatment of Patients Following Hemorrhagic Trauma (MATRICS-1) and for the Treatment of Ischemic Stroke (MASTERS-2)

Athersys, Inc. Appoints Joseph Nolan to Its Board of Directors

Athersys Receives A Written Notice from Nasdaq Regarding Bid Price Requirement

CEO, Secretary recently bought US$55k worth of stock

Athersys, Inc. to Report Q3, 2022 Results on Nov 15, 2022

Athersys, Inc. Announces the Resignation of Kenneth H. Traub from the Board of Directors

Athersys Receives Non-Compliance Letter from Nasdaq

Athersys: Is Big Pharma Sleeping At The Wheel?

Athersys extends exercise period of warrants in connection with recent offering

Athersys announces 1-for-25 reverse stock split

One Analyst's Revenue Estimates For Athersys, Inc. (NASDAQ:ATHX) Are Surging Higher

Athersys stock falls ~9% after reporting Q2 loss, fall in cash and cash equivalents

Athersys, Inc. Announces Favorable Preclinical Results for MultiStem Treatment in Defense Department Radiation Countermeasure Study

Athersys, Inc. Appoints Kasey Rosado as Interim Chief Financial Officer

Kasey Rosado named interim CFO of Athersys

Athersys, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Athersys: Dead Man Walking

Athersys, Inc. Designates Dan Camardo as the Principal Financial Officer and Principal Accounting Officer

Athersys, Inc. Announces Board Changes

Athersys, Inc. Announces Management Changes

Athersys, Inc., Annual General Meeting, Jun 15, 2022

Consensus forecasts updated

Athersys: Focus On Stroke

Athersys, Inc. to Report Q1, 2022 Results on May 06, 2022

Price target decreased to US$3.33

Athersys - Hero Or Zero Opportunity

Consensus revenue estimates fall by 70%

Price target decreased to US$3.33

Consensus forecasts updated

Price target increased to US$5.00

Athersys, Inc. to Report Q4, 2021 Results on Mar 15, 2022

Athersys, Inc. to Present an Outlook of its Ischemic Stroke Program Including Perspectives on the Upcoming TREASURE Study Data Readout

Athersys: Near-Term Progress In Stem Cell Phase 3 Trials Could Multiply Shares In 2022

Here's Why Athersys (NASDAQ:ATHX) Must Use Its Cash Wisely

Athersys, Inc. Announces Manuscript Reporting Data from the Company’s Must-ARDS Clinical Trial

Athersys: COVID-ARDS Is The Company's Most Important Target

Price target decreased to US$3.75

Third quarter 2021 earnings released: US$0.071 loss per share (vs US$0.11 loss in 3Q 2020)

Price target decreased to US$4.67

Athersys Shares Are Ready To Rumble Following Period Of Turmoil

Consensus forecasts updated